Project Grant R21AI181258
- Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,000 Project Grant to the University of Texas at Dallas under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2027. This research project develops innovative measurement methodologies to characterize the spatial distribution of chemicals and pathogens within bioaerosols, with particular focus on understanding how virus viability is affected by...
- This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
- This Project Grant award from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program (CFDA 47.070) provides $150,000 to the University of Illinois to develop proactive solutions for public health protection against airborne diseases. The key objectives are: Create an intelligent, automated system for real-time, multiplex monitoring of critical airborne pathogens, including the ability to obtain time-resolved measurements of infectious aerosols...
- This National Science Foundation project grant of $214,373 awarded to Arizona State University on April 1, 2022 through the Engineering (47.041) federal grant program will fund collaborative research examining the fluid dynamics of respiratory virus transport through lung liquid lining. Specifically, the award will support experiments and numerical modeling to capture the essential fluid interactions between lung surfactants and a model virus, simulating physiologically relevant scales....
- This $200,000 Project Grant from the National Science Foundation Division of Environmental Biology supports research investigating the uptake, persistence, and impact of behavioral interventions on respiratory viruses. Funded under the Biological Sciences program (CFDA 47.074), the Pennsylvania State University will model the dynamics of COVID-19 and influenza transmission considering behavioral changes mandated by public health interventions as well as voluntary individual behaviors....
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $451,000 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 1, 2026, for a two-year project concluding March 31, 2028. The grant funds development of the Digital Droplet Aerosol Capture & Quantification (DDACQ) system, a portable technology platform designed to enable rapid detection and quantitative...
- This $968,765 Project Grant awarded by the National Science Foundation's (NSF) Division of Mathematical Sciences (CFDA 47.049 - Mathematical and Physical Sciences) will develop a flexible modeling framework to simulate the impact of various testing-based infection control strategies for respiratory pathogens like SARS-CoV-2. The project aims to improve our ability to control existing respiratory diseases and enhance preparedness for future pandemics. Key deliverables include: Developing a...
- This $249,999 National Science Foundation project grant supports the development of a bioengineered nanobarrier spray to protect against SARS-CoV-2 and other viral infections of the nasopharynx. Funded under the NSF Engineering program (CFDA 47.041), the two-year award to the University of Southern California will support computational modeling of nanobarrier delivery via nasal applicator as well as efficacy testing in a coronavirus mouse model. Specifically, the university researchers will...
- This $255,870 National Science Foundation Technology, Innovation, and Partnerships grant to Strivision LLC supports the development of an airborne contagion mapping platform through visual exhale monitoring. The goal is to create a method for monitoring and evaluating exposure risks from airborne viral contaminants such as COVID-19 to reduce public health risks from respiratory disease transmission. Strivision will advance understanding of how airborne contagions spread within indoor spaces by...
- This $195,101 Project Grant, awarded by the National Science Foundation's (NSF) Biological Sciences program (CFDA 47.074), will use mathematical modeling to project the healthcare burden associated with COVID-19, influenza, and respiratory syncytial virus (RSV) in the United States during the 2023-2024 respiratory virus season. The research will integrate estimates of population immunity from prior infections, vaccinations, and monoclonal antibody therapy to produce four rounds of projections...
PROBING THE PARTICLE SIZE-VIABILITY RELATIONSHIP IN BIOAEROSOLS THROUGH SIZE-CONTROLLED MEASUREMENTS - ABSTRACT BIOAEROSOLS ARE SMALL PARTICLES SUSPENDED IN THE AIR THAT CONTAIN LIVING ORGANISMS SUCH AS BACTERIA, FUNGI, AND VIRUSES, AND HAVE CAUSED SOME OF THE MOST SEVERE AND COSTLY DISEASES, INCLUDING THE SARS-COV-2 PANDEMIC. AMONG THE VARIOUS FACTORS, THE BIOAEROSOL PARTICLE SIZE PLAYS A CRUCIAL ROLE IN ALL STAGES OF TRANSMISSION, INCLUDING THE GENERATION LOCATIONS AND MECHANISMS IN THE HOST'S RESPIRATORY SYSTEM, THE SUSPENSION TIME AND THE TRAVELING DISTANCE (SHORT-RANGE VS. LONG-RANGE), AND THE FINAL DEPOSITION EFFICIENCY AND LOCATION INTO THE RECIPIENT'S RESPIRATORY SYSTEM. DESPITE SIGNIFICANT INTEREST IN THIS AREA OVER THE PAST FEW YEARS, CURRENT METHODS TO GENERATE BIOAEROSOLS CANNOT PRODUCE BIOAEROSOLS WITH UNIFORM SIZE AND SUFFICIENT QUANTITY TO ALLOW RELIABLE MEASUREMENT OF PATHOGENS THAT REMAIN INFECTIOUS OVER A LONG TIME PERIOD. FURTHERMORE, NO SINGLE METHOD CAN COVER THE COMPLETE SIZE RANGE OF BIOAEROSOLS FROM THE HUMAN RESPIRATORY SYSTEM. AS A RESULT, THE FIELD HAS SUFFERED FROM THE LACK OF CAPABILITY TO STUDY IMPORTANT AND BASIC QUESTIONS, INCLUDING HOW SIZE IN THE ENTIRE RESPIRABLE BIOAEROSOL RANGE AND RESPIRATORY ACTIVITIES (COUGHING, SPEAKING, SNEEZING, ETC.) INFLUENCES HOW INFECTIOUS PATHOGENS TRANSMIT UNDER DIFFERENT ENVIRONMENTAL CONDITIONS (SUCH AS RELATIVE HUMIDITY, UV LIGHTS, VENTILATION). THIS PROPOSED RESEARCH AIMS TO ADDRESS THESE CRITICAL LIMITATIONS. OUR CENTRAL HYPOTHESIS IS THAT THE BIOAEROSOL SIZE AND SIZE DISTRIBUTION DUE TO RESPIRATORY ACTIVITIES HAVE A SIGNIFICANT IMPACT ON HOW THE AIRBORNE PATHOGENS STAY INFECTIOUS IN THE AIR AS A FUNCTION OF ENVIRONMENTAL CONDITIONS, AND A VIRTUAL IMPACT DESIGN PRODUCES MONODISPERSE PATHOGEN-LADEN BIOAEROSOLS AND IN SUFFICIENT QUANTITIES TO DETECT LIVE PATHOGENS TO STUDY THE SIZE-VIABILITY DECAY RATE RELATIONSHIP. WE WILL TEST RESPIRATORY SYNCYTIAL VIRUS (RSV), WHICH DISPROPORTIONALLY AFFECTS INFANTS UNDER 2 YEARS OLD. IT IS CRITICAL TO UNDERSTAND HOW RSV IS TRANSMITTED WHILE THERE IS SCARCE DATA IN THE AREA OF RSV TRANSMISSION STUDIES. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO DESIGN AND BUILD AN EASY-TO-MANUFACTURE AND EASY-TO-USE BIOAEROSOLS GENERATION SYSTEM AND INVESTIGATE THE CRUCIAL ROLE OF SIZE IN THE BIOAEROSOL VIABILITY DECAY UNDER VARIOUS ENVIRONMENTAL CONDITIONS. OUR SPECIFIC AIMS ARE (1) TO DETERMINE THE SIZE-VIABILITY DECAY RELATIONSHIP FOR RSV WITH MONODISPERSE BIOAEROSOLS AND (2) TO ESTIMATE THE VIABILITY DECAY RATE OF DIFFERENT RESPIRATORY ACTIVITIES WITH A FEW WELL-CHARACTERIZED LOG-NORMAL DISTRIBUTIONS. THE SUCCESS OF THIS PROPOSED WORK WILL PROVIDE A NEW SCIENTIFIC TOOL TO GENERATE MONODISPERSED BIOAEROSOLS WITH SUFFICIENT QUANTITY FOR VIABILITY ASSAYS AND ELUCIDATE THE KEY CONTRIBUTION OF BIOAEROSOL SIZE ON PATHOGEN VIABILITY IN DIFFERENT ENVIRONMENTAL CONDITIONS. FURTHERMORE, OUR WORK WILL REVEAL HOW RESPIRATORY ACTIVITIES IMPACT PATHOGEN TRANSMISSION. THESE TOOLS AND INSIGHTS CAN LEAD TO FUTURE STUDIES ON BIOAEROSOL DEPOSITION IN RODENT AND NON-HUMAN PRIMATE LUNG MODELS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/13/26 | ||
| Not listed | $195.0k | 4/16/25 | ||
| Not listed | $19.5k | 9/11/24 | ||
| Not listed | $19.5k | 9/11/24 | ||
| Not listed | $175.5k | 6/18/24 |